Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-cell Non–Hodgkin Lymphoma (CAPITAL)
The study was terminated early with a small sample size, limiting interpretation, although antitumor activity was limited. Future studies of capivasertib in hematologic malignancies would likely require biomarker-directed patient selection and/or combination therapy.
Authors
- Geoffrey Shouse (ORCID: https://orcid.org/0000-0002-7917-5713)
- Macarena Izuzquiza
- V. Ribrag
- Alex Francisco Herrera (ORCID: https://orcid.org/0000-0002-9665-7415)
- Güllü Görgün
- Veerendra Munugalavadla (ORCID: https://orcid.org/0000-0002-2390-3822)
- Daniel J. Hodson (ORCID: https://orcid.org/0000-0001-6225-2033)
- Nicol Macpherson
- Nisha Sambamurthy
- Michael L. Wang (ORCID: https://orcid.org/0000-0001-9748-5486)
- Jin Seok Kim (ORCID: https://orcid.org/0000-0003-0166-2084)
- ANAS YOUNES
- Sergio Vicente
- Robert Chen
- Antonio Salar
- Stephanie Guidez
- Dachelle Colton
- Sabela Bobillo
- Raul Cordoba
- Ho-Jin Shin
- Franck Morschhauser
Institutions
- BC Cancer Agency (CA)
- The University of Texas MD Anderson Cancer Center (US)
- Yonsei University (KR)
- Wellcome/MRC Cambridge Stem Cell Institute (GB)
- Institut Gustave Roussy (FR)
- Centre Hospitalier Universitaire de Lille (FR)
- AstraZeneca (South Korea) (KR)
- AstraZeneca (Australia) (AU)
- City of Hope (US)
- Centre Hospitalier Universitaire de Poitiers (FR)
- AstraZeneca (Netherlands) (NL)
- AstraZeneca (Singapore) (SG)
- Pusan National University Hospital (KR)
- AstraZeneca (Brazil) (BR)
- Vall d'Hebron Hospital Universitari (ES)
- AstraZeneca (Switzerland) (CH)
- Hospital Universitario Fundación Jiménez Díaz (ES)
- Hospital Del Mar (ES)
- Stem Cell Institute (PA)
- AstraZeneca (United States) (US)
- Universidad de Murcia (ES)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-12-22
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-2239
- Primary Topic
- PI3K/AKT/mTOR signaling in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company
- AstraZeneca
- Gilead Sciences
- Astex Pharmaceuticals
- BeiGene
- Kite Pharma